Latebreakers: New beta-blocker Bystolic gets FDA nod

Beta-blocker nebivolol (Bystolic), from both Forest Laboratories and Mylan, Inc., has been approved by the FDA for the treatment of hypertension. The new molecular entity is orally available and can be used alone or in combination with other antihypertensive agents. According to the manufacturer, nebivolol works by decreasing heart rate and contractility and suppressing renin activity. The drug is a selective beta-1 blocker and is available in 2.5-mg, 5-mg, and 10-mg tablets.